A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
Latest Information Update: 22 Mar 2024
At a glance
- Drugs SHR 1901 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 19 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 22 Jan 2022 New trial record